cd19 microbeads (Miltenyi Biotec)
Miltenyi Biotec is a verified supplier 
Miltenyi Biotec manufactures this product 
96
Structured Review
Miltenyi Biotec
cd19 microbeads
Cd19 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 922 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+cd19/CD19+MicroBeads%2C+mouse/bio_rxiv__64898__2026__10__12__756217-223-7-9
Average 96 stars, based on 922 article reviews
Cd19 Microbeads, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 96/100, based on 922 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mouse+cd19/CD19+MicroBeads%2C+mouse/bio_rxiv__64898__2026__10__12__756217-223-7-9
Average 96 stars, based on 922 article reviews
cd19 microbeads - by Bioz Stars,
2026-11
96/100 stars
Images
1) Product Images from "Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures"
Article Title: Co-targeting KRAS and BCL-2 induces pyroptosis and antitumor tertiary lymphoid structures
Journal: bioRxiv
doi: 10.64898/2026.10.12.756217
Figure Legend Snippet: a, b, Antitumor efficacy of combination treatment in KP-1 and FC1242 subcutaneous xenograft models. n = 8 mice per group. c, Lymphoid immune cell composition in KP1 tumors. n = 6 per group. d, Myeloid immune cell composition in KP1 tumors. n = 6 per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Techniques Used: Xenograft Assay, Immune Cell
Figure Legend Snippet: a, H&E staining of tumor sections from combination treatment groups. b, Multiplex immunofluorescence staining for CD3, CD19, CD23, and CD31 on tumor sections from the combination treatment group. c, Multiplex immunofluorescence staining for CD138, IgG and IgA on tumor sections from vehicle and combination treatment groups. d, Quantification of the CD138+ cell / mm 2 and IgG/IgA ratio in tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. e, UMAP plots of B cells at indicated time points post-treatment. f, BCR repertoire diversity, clonal dynamics, and SHM following combination treatment. g, Immunoglobulin isotype distribution of B cells over the treatment time course. h, Peripheral BCR repertoire diversity and SHM following combination treatment. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Techniques Used: Staining, Multiplex Assay, Immunofluorescence
Figure Legend Snippet: a, Experimental schematic of the in vivo depletion and adoptive transfer study design. b, Tumor growth curves of mice treated with the combination regimen following depletion of B cells, CD4+ T cells, CD8+ T cells, NK cells, or FcyR blockade. n = 5-8 mice per group. c, Multiplex immunofluorescence staining for C3d, IgG, and CK8/18 on tumor sections from vehicle, single-agent, and combination treatment groups. n = 3 per group. d, Quantification of memory B cells in the spleen and tumor-draining lymph nodes from vehicle and combination treatment groups by flow cytometry. n = 4 per group. e, Quantification of long-lived plasma cells in the bone marrow from vehicle and combination treatment groups by flow cytometry. n = 5 per group. f, Serum levels of tumor-specific antibodies measured by flow cytometry in vehicle and combination treatment groups. n = 3-5 per group. g, (Left) Quantification of plasma cells generated from CD19+ splenocytes stimulated with tumor antigens in vitro. (Right) IgG binding to tumor cells detected by flow cytometry after incubation with culture supernatants from vehicle or combination treatment groups. h, Tumor volume curves of naive recipient mice receiving adoptive transfer of B cells or T cells from vehicle- or combination-treated donor mice, followed by tumor inoculation and half-dose RMC-6236 administration. n = 7 mice per group. i, Rechallenge tumor growth in non-CR and treatment-naive mice. n = 8 mice per group. Statistical significance was determined by one-way ANOVA test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001.
Techniques Used: In Vivo, Adoptive Transfer Assay, Multiplex Assay, Immunofluorescence, Staining, Flow Cytometry, Clinical Proteomics, Generated, In Vitro, Binding Assay, Incubation
Related Articles
Selection:Article Title: Alternative pathway for the development of V α 14 + NKT cells directly from CD4 - CD8 - thymocytes that bypasses the CD4 + CD8 + stage. Article Snippet: Natural killer T cells (NKT cells) are characterized by the expression of a unique T cell antigen receptor (TCR) α-chain composed of a single invariant α-chain variable region 14–α-chain joining region 18 (Vα14Jα18) in mice1 and Vα24Jα18 in humans2,3, both of which recognize almost identical glycolipid-binding sites contributed mainly by the proximal Jα18 region4.. Thus, both human NKT cells and mouse NKT cells recognize the same glycolipid ligands, such as α-galactosylceramide (α-GalCer), in conjunction with the monomorphic major histocompatibility complex (MHC)-like antigen-presenting molecule CD1d5,6 and show cross-species reactivity7.. The majority of NKT cells are T-helper-type-1 (TH1)-type NKT cells, which have important protective roles in responses to tumors or pathogens due to their very rapid and powerful innate-like responses. Marker:Article Title: SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu- 3 cells were retrovirally transduced with a pLZRS vector containing the HLA- B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described (Jahn et al., 2015). .. Article Title: Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens Article Snippet: .. Cells were infected with pseudotyped lentiviruses, and 72 hours later, were harvested and stained with antibodies against the relevant surface marker: Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site (IRES) sequence to mouse CD19, transduction was performed as previously described ( ). .. Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described ( ). .. Staining:Article Title: SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu- 3 cells were retrovirally transduced with a pLZRS vector containing the HLA- B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described (Jahn et al., 2015). .. Article Title: Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens Article Snippet: .. Cells were infected with pseudotyped lentiviruses, and 72 hours later, were harvested and stained with antibodies against the relevant surface marker: Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site (IRES) sequence to mouse CD19, transduction was performed as previously described ( ). .. Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described ( ). .. Magnetic Cell Separation:Article Title: SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu- 3 cells were retrovirally transduced with a pLZRS vector containing the HLA- B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described (Jahn et al., 2015). .. Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site (IRES) sequence to mouse CD19, transduction was performed as previously described ( ). .. Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described ( ). .. FACS:Article Title: SARS-CoV-2-specific CD4+ and CD8+ T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu- 3 cells were retrovirally transduced with a pLZRS vector containing the HLA- B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described (Jahn et al., 2015). .. Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site (IRES) sequence to mouse CD19, transduction was performed as previously described ( ). .. Article Title: SARS-CoV-2-specific CD4 + and CD8 + T cell responses can originate from cross-reactive CMV-specific T cells Article Snippet: Calu-3 cells were retrovirally transduced with a pLZRS vector containing the HLA-B*35:01 molecule linked via an internal ribosome entry site sequence to mouse CD19, and transduction was performed as previously described ( ). .. Infection:Article Title: Elucidating genes sufficient for viral entry into cells through sequential genome-wide CRISPR activation screens Article Snippet: .. Cells were infected with pseudotyped lentiviruses, and 72 hours later, were harvested and stained with antibodies against the relevant surface marker: |